HUTCHMED DRC

Yahoo Finance • 16 days ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification

— NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 — — Savolitinib has the potential to become the first selective MET inhibitor in China for MET-ampl... Full story

Yahoo Finance • 17 days ago

Hutchmed's NDA For Fanregratinib In Intrahepatic Cholangiocarcinoma Accepted In China

(RTTNews) - Hutchmed China Ltd. (HCM, HCM.L) announced Monday that the China National Medical Products Administration (NMPA) has accepted and granted priority review for New Drug Application or NDA for fanregratinib (HMPL-453) to treat adu... Full story

Yahoo Finance • 17 days ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

— NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in comparison — HONG KONG and SHANGHAI and FLORHA... Full story

Yahoo Finance • 30 days ago

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors

— First-in-human trial of candidate from the next-generation ATTC platform — — Simultaneous China and global clinical development strategy to expedite development process — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 17, 2025 (... Full story

Yahoo Finance • last month

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal with the China National Healthcare Sec... Full story

Yahoo Finance • 2 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by... Full story

Yahoo Finance • 2 months ago

HUTCHMED Breaks Below 200-Day Moving Average - Notable for HCM

In trading on Friday, shares of HUTCHMED (China) Ltd (Symbol: HCM) crossed below their 200 day moving average of $17.19, changing hands as low as $17.15 per share. HUTCHMED (China) Ltd shares are currently trading off about 1.6% on the da... Full story

Yahoo Finance • 2 months ago

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference (“dbVIC”) held Novem... Full story

Yahoo Finance • 2 months ago

HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SAFFRON, a global Phase III study... Full story

Yahoo Finance • 2 months ago

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action — — Lead candidate HMPL-A251 harnesses a selective PI3K/PIKK inhibitor payload, demonstrating promising pr... Full story

Yahoo Finance • 3 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, November 04, 2025, featuring live webcast presentations from international... Full story

Yahoo Finance • 3 months ago

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

— First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities — — Unique, highly potent PI3K/PIKK inhibitor payload optimized to exploit a... Full story

Yahoo Finance • 3 months ago

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is ap... Full story

Yahoo Finance • 3 months ago

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announces results from the FRUSICA-2 registration clinical trial of the fruquintinib and s... Full story

Yahoo Finance • 3 months ago

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by... Full story

Yahoo Finance • 4 months ago

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a Research & Development update in Shanghai, China, and v... Full story

Yahoo Finance • 4 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by... Full story

Yahoo Finance • 5 months ago

HUTCHMED CEO takes leave of absence; CFO Johnny Cheng appointed acting CEO

HUTCHMED (HCM [https://seekingalpha.com/symbol/HCM]) has announced [https://seekingalpha.com/pr/20209647-hutchmed-announces-appointment-of-acting-chief-executive-officer] that CEO Weiguo Su will take a leave of absence for health reasons.... Full story

Yahoo Finance • 5 months ago

HUTCHMED Announces Appointment of Acting Chief Executive Officer

HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave... Full story

Yahoo Finance • 5 months ago

Thailand Construction Equipment Market Report 2025-2030 - Booming Manufacturing Drives Material Handling Equipment Demand in Thailand

Dublin, Aug. 22, 2025 (GLOBE NEWSWIRE) -- The "Thailand Construction Equipment Market Research Report 2025-2030" has been added to ResearchAndMarkets.com's offering. The Thailand Construction Equipment Market was sized at 14,786 unit... Full story